Next step in the development of mesoprogestins: the preclinical profile of EC313

IntroductionThe pharmacological target for progesterone, different progestins, and Selective Progesterone Receptor Modulators (SPRMs) is the nuclear progesterone receptor (PR). EC313 is a new member of a subgroup of SPRMs, mesoprogestins, which combine especially PR- agonistic and PR-antagonistic ac...

Full description

Bibliographic Details
Main Authors: K. Błaszczak-Świątkiewicz, A. Krupa, E. Mnich, W. Elger, M. Oettel, H. Nair, M. Wierzbicki, P. Sieroszewski, Z. Shaked
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1201547/full